



VACCINE AND INFECTIOUS DISEASE ORGANIZATION



SOLUTIONS

THROUGH RESEARCH



COVID-19 SUPPORT

VIDO provides services to groups developing vaccines, antivirals and therapeutics against COVID-19. This includes:

- *In vitro* testing: assessing antiviral and/or viral neutralization effect of compounds against SARS-CoV-2.
- *In vivo* testing: use our established SARS-CoV-2 challenge models in ferrets and hamsters to test the efficacy of vaccines, antivirals and other therapeutics.



WORLD-CLASS SCIENCE

pathogenesis • vaccine development and formulation • vaccine and drug efficacy and immunogenicity testing

The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan is a world leader in advancing human and animal health. We have over 45 years of research and development experience that has resulted in eight commercial vaccines - six of which were 'world-firsts'.

Industry partners benefit from our scientific expertise, state-of-the-art facilities, and broad service offerings. Our large research capacity promotes shorter development timelines and an enhanced return on investment.

Our goal is to expedite new technology development to ensure humans and animals are protected from emerging infectious diseases.

EXAMPLE DISEASE MODELS											
CL3	Chronic wasting disease*				●						
	Influenza									●	●
	Middle East respiratory syndrome					●			●		
	<i>Mycobacterium tuberculosis/bovis</i>	●	●				●				●
	<i>Pasteurella multocida</i> ***	●									●
CL2	SARS-CoV-2									●	●
	<i>Actinobacillus pleuropneumoniae</i>						●				
	<i>Bordetella spp.</i>						●				●
	Bovine viruses (BHV-1, BVDV)	●									
	<i>Campylobacter jejuni</i>							●			
	<i>Escherichia coli</i> (STEC, APEC, F41)	●					●		●		●
	Infectious bursal disease virus							●			
	Influenza			●			●			●	●
	<i>Lawsonia intracellularis</i>						●				
	<i>Mannheimia haemolytica</i>	●						●			
	<i>Mycobacterium paratuberculosis</i>	●									
	<i>Mycoplasma spp.</i>	●									
	Respiratory syncytial virus	●						●			●
	<i>Rhodococcus equi</i>			●							
	<i>Salmonella spp.</i>								●		●
	Scrapie							●			
	STIs (<i>Neisseria</i> , <i>Chlamydia</i>)						●				●
<i>Staphylococcus aureus</i>	●						●			●	
<i>Streptococcus spp.</i>	●					●					
Swine viruses (PEDV, PCV, PRRSV)						●					
Zika virus						●				●	

* Risk group 2+ working in level 3 containment, ** Cotton rat and/or golden hamster and/or rat and/or mouse, *** Serotypes B and E Models currently in development ●

We offer >

A FULL RANGE OF SERVICES

- Study design
- Animal model development
- Host-pathogen interaction studies
- Pre-clinical studies for human vaccines, antivirals and therapeutics
- Full regulatory studies for veterinary vaccines, antivirals and therapeutics
- *In vitro* assessments of antimicrobial activity including VNs
- Serial release testing for veterinary vaccines

EXTENSIVE BIOSAFETY LEVEL 2 AND 3 CAPACITY

- One of the largest and most advanced high containment facilities in the world
- Significant animal housing capacity for all species
- Aerobiology challenge units
- Cellular analysis, whole animal imaging, clinical pathology, surgery, necropsy and histology

QUALITY AND CARE

- Certified project managers
- Access to over 45 PhD level scientists
- Dedicated animal care team including clinical research veterinarians and technicians
- ISO 9001:2015 certified management system
- Certificate of Good Animal Practice®


 Scientists from **25+ countries**

Certified to
**ISO
9001**



> \$225M
in biocontainment infrastructure

45+
PhD level **scientists**



LOCATED IN
Saskatchewan, Canada

150 **infectious disease
& vaccine studies**
conducted annually



8 commercialized
vaccines... **6 world firsts**

For more information contact:

PAUL HODGSON

Associate Director - Business Development

306-966-7465

paul.hodgson@usask.ca



UNIVERSITY OF
SASKATCHEWAN

www.vido.org